Amgen (AMGN): LDL Guidelines Favorable For Amgen - Cowen

July 20, 2017 7:18 AM EDT
Get Alerts AMGN Hot Sheet
Price: $248.39 +0.02%

Rating Summary:
    15 Buy, 19 Hold, 3 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 40 | New: 22
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst, Eric Schmidt, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after the draft 2017 LDL treatment guidelines from the ACC became available on-line. He believes they are "quite favorable to Amgen".

The analyst stated "if these guidelines are enacted, they would support the use of anti-PCSK9 therapy in a much broader patient population and potentially reduce step editing. Our reimbursement consultants believe updated treatment guidelines are the most important driver of expanded access".

No change to the price target of $209.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $179.18 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Cowen & Co